Zoe Newell Swank

Zoe Newell Swank is part of a research group that has been working on the development project for simple, low-cost molecular diagnostic tests using cell-free systems. This lab will repurpose a high-throughput microfluidic diagnostics platform that it developed, so it can be used in SARS-CoV-2 serological assays. The platform will allow more tests to be conducted with significantly reduced reagent consumption. This line of research is relevant to the diagnosis and testing of COVID-19.
Country: Switzerland
Visit Website
Zoe.Swank@epfl.ch